Treatment of EBV and KHSV infection
First Claim
1. A method for treating an animal infected with Epstein-Barr virus or KHSV comprising administering to said animal an effective amount of a compound or pharmaceutically acceptable salt thereof, said compound is selected from the group consisting of (2S,4S)-5-(2-furanyl)-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]uracil, (2S,4S)-5-(5-bromo-2-furanyl)-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]uracil, (2S,4S)-5-(2-thienyl)-1-[2-2-(hydroxymethyl)-1,3-dioxolan-4-yl]uracil and (2S,4S)-5-(5-bromthien-2-yl))-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]uracil.
8 Assignments
0 Petitions
Accused Products
Abstract
A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
36 Citations
10 Claims
- 1. A method for treating an animal infected with Epstein-Barr virus or KHSV comprising administering to said animal an effective amount of a compound or pharmaceutically acceptable salt thereof, said compound is selected from the group consisting of (2S,4S)-5-(2-furanyl)-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]uracil, (2S,4S)-5-(5-bromo-2-furanyl)-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]uracil, (2S,4S)-5-(2-thienyl)-1-[2-2-(hydroxymethyl)-1,3-dioxolan-4-yl]uracil and (2S,4S)-5-(5-bromthien-2-yl))-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]uracil.
Specification